Bayer: submits CKD treatment for approval in China
(CercleFinance.com) - Germany's Bayer said on Tuesday that it has submitted its drug finerenone, which is for the treatment of chronic kidney disease (CKD) in patients with type 2 diabetes, for approval in China.
In a statement, Bayer announced the submission of a regulatory application to China's National Medical Products Administration (NMPA), seeking approval of finerenone for the treatment of patients with chronic kidney disease and type 2 diabetes.
Chronic kidney disease can shorten life expectancy of type 2 diabetes patients by up to 16 years, the drugmaker said.
Bayer also announced that it has expanded its development program with Finland's Orion for darolutamide in prostate cancer, with a Phase III study to be initiated in metastatic hormone-sensitive prostate cancer (mHSPC) by the end of the first quarter.
Finally, Bayer said that it has presented new data at the 2021 ASCO genitourinary cancers symposium adding to robustness of the overall survival benefit and favourable safety profile for its new prostate cancer drug Nubeqa.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
In a statement, Bayer announced the submission of a regulatory application to China's National Medical Products Administration (NMPA), seeking approval of finerenone for the treatment of patients with chronic kidney disease and type 2 diabetes.
Chronic kidney disease can shorten life expectancy of type 2 diabetes patients by up to 16 years, the drugmaker said.
Bayer also announced that it has expanded its development program with Finland's Orion for darolutamide in prostate cancer, with a Phase III study to be initiated in metastatic hormone-sensitive prostate cancer (mHSPC) by the end of the first quarter.
Finally, Bayer said that it has presented new data at the 2021 ASCO genitourinary cancers symposium adding to robustness of the overall survival benefit and favourable safety profile for its new prostate cancer drug Nubeqa.
Copyright (c) 2021 CercleFinance.com. All rights reserved.